Bionomics Ltd (BNOX)

$0.6

-0.01

(-1.7%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.58
    $0.64
    $0.60
    downward going graph

    3.33%

    Downside

    Day's Volatility :9.94%

    Upside

    6.83%

    downward going graph
  • $0.50
    $6.41
    $0.60
    downward going graph

    16.58%

    Downside

    52 Weeks Volatility :92.19%

    Upside

    90.64%

    downward going graph

Returns

PeriodBionomics LtdIndex (Russel 2000)
3 Months
-16.2%
0.0%
6 Months
-49.15%
0.0%
1 Year
-67.49%
0.0%
3 Years
-95.96%
-22.3%

Highlights

Market Capitalization
7.9M
Book Value
$2.72
Earnings Per Share (EPS)
-2.05
Wall Street Target Price
6.0
Profit Margin
0.0%
Operating Margin TTM
-9466.24%
Return On Assets TTM
-35.13%
Return On Equity TTM
-80.8%
Revenue TTM
662.0K
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
9.3%
Gross Profit TTM
-19.0M
EBITDA
-25.7M
Diluted Eps TTM
-2.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Bionomics Ltd(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 900.0%

Current $0.60
Target $6.00

Company Financials

FY18Y/Y Change
Revenue
6.6M
↓ 57.7%
Net Income
-13.9M
↑ 257.91%
Net Profit Margin
-211.13%
↓ 186.18%
FY19Y/Y Change
Revenue
3.6M
↓ 41.21%
Net Income
-5.1M
↓ 60.66%
Net Profit Margin
-141.25%
↑ 69.88%
FY20Y/Y Change
Revenue
1.4M
↓ 60.06%
Net Income
-2.8M
↓ 45.01%
Net Profit Margin
-194.47%
↓ 53.22%
FY21Y/Y Change
Revenue
531.5K
↓ 66.3%
Net Income
-5.0M
↑ 62.39%
Net Profit Margin
-937.11%
↓ 742.64%
FY22Y/Y Change
Revenue
2.9M
↑ 500.75%
Net Income
-10.6M
↑ 130.36%
Net Profit Margin
-359.34%
↑ 577.77%
FY23Y/Y Change
Revenue
290.7K
↓ 89.65%
Net Income
-14.2M
↑ 41.19%
Net Profit Margin
-4.9K%
↓ 4543.17%
Q3 FY22Q/Q Change
Revenue
2.7M
↑ 6065.76%
Net Income
-4.0M
↑ 10.49%
Net Profit Margin
-147.91%
↑ 8105.71%
Q4 FY22Q/Q Change
Revenue
61.0K
↓ 97.78%
Net Income
-7.4M
↑ 83.57%
Net Profit Margin
-12.2K%
↓ 12058.48%
Q1 FY23Q/Q Change
Revenue
172.6K
↑ 185.87%
Net Income
-5.2M
↓ 29.13%
Net Profit Margin
-3.0K%
↑ 9180.4%
Q2 FY23Q/Q Change
Revenue
31.3K
↓ 81.94%
Net Income
-3.3M
↓ 36.83%
Net Profit Margin
-10.6K%
↓ 7561.32%
Q3 FY23Q/Q Change
Revenue
344.2K
↑ 637.78%
Net Income
-10.4M
↑ 110.87%
Net Profit Margin
-3.0K%
↑ 7561.31%
Q4 FY23Q/Q Change
Revenue
98.9K
↓ 71.26%
Net Income
-10.5M
↑ 0.56%
Net Profit Margin
-10.6K%
↓ 7561.33%
FY18Y/Y Change
Total Assets
36.1M
↓ 25.47%
Total Liabilities
26.7M
↑ 6.2%
FY19Y/Y Change
Total Assets
26.2M
↓ 21.77%
Total Liabilities
18.1M
↓ 26.73%
FY20Y/Y Change
Total Assets
16.4M
↓ 36.87%
Total Liabilities
10.4M
↓ 42.38%
FY21Y/Y Change
Total Assets
31.1M
↑ 71.08%
Total Liabilities
3.8M
↓ 66.75%
FY22Y/Y Change
Total Assets
31.7M
↑ 10.82%
Total Liabilities
4.1M
↑ 15.99%
FY23Y/Y Change
Total Assets
19.2M
↓ 36.48%
Total Liabilities
4.4M
↑ 13.23%
Q3 FY22Q/Q Change
Total Assets
30.2M
↓ 30.96%
Total Liabilities
3.9M
↓ 30.96%
Q4 FY22Q/Q Change
Total Assets
25.9M
↓ 14.99%
Total Liabilities
3.9M
↑ 0.84%
Q1 FY23Q/Q Change
Total Assets
10.9M
↓ 57.41%
Total Liabilities
1.4M
↓ 64.09%
Q2 FY23Q/Q Change
Total Assets
16.8M
↑ 52.97%
Total Liabilities
4.2M
↑ 200.68%
Q3 FY23Q/Q Change
Total Assets
18.4M
↑ 14.68%
Total Liabilities
4.2M
↑ 4.0%
Q4 FY23Q/Q Change
Total Assets
17.7M
↓ 7.55%
Total Liabilities
4.5M
↑ 1.95%
FY18Y/Y Change
Operating Cash Flow
-11.3M
↑ 1267.92%
Investing Cash Flow
60.9K
-
Financing Cash Flow
1.5M
↓ 221.9%
FY19Y/Y Change
Operating Cash Flow
-7.6M
↓ 27.74%
Investing Cash Flow
137.3K
↑ 143.28%
Financing Cash Flow
2.1M
↑ 56.71%
FY20Y/Y Change
Operating Cash Flow
-2.7M
↓ 64.32%
Investing Cash Flow
-134.6K
↓ 198.72%
Financing Cash Flow
-3.7M
↓ 275.33%
FY21Y/Y Change
Operating Cash Flow
-5.8M
↑ 93.14%
Investing Cash Flow
-61.3K
↓ 58.9%
Financing Cash Flow
24.1M
↓ 689.02%
FY22Y/Y Change
Operating Cash Flow
-10.6M
↑ 99.24%
Investing Cash Flow
437.0K
↓ 875.13%
Financing Cash Flow
13.1M
↓ 40.93%
FY23Y/Y Change
Operating Cash Flow
-9.5M
↓ 5.36%
Investing Cash Flow
322.1K
↓ 22.87%
Financing Cash Flow
2.5M
↓ 80.14%
Q3 FY22Q/Q Change
Operating Cash Flow
-4.1M
↑ 13.16%
Investing Cash Flow
64.0K
↑ 2486.63%
Financing Cash Flow
1.1M
↓ 366.99%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.1M
↓ 0.37%
Investing Cash Flow
64.5K
↑ 0.0%
Financing Cash Flow
2.7M
↑ 142.54%
Q1 FY23Q/Q Change
Operating Cash Flow
-435.5K
↓ 89.37%
Investing Cash Flow
96.3K
↑ 50.93%
Financing Cash Flow
-204.4K
↓ 107.55%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.1M
↑ 605.27%
Investing Cash Flow
96.9K
↑ 0.0%
Financing Cash Flow
2.4M
↓ 1263.52%

Technicals Summary

Sell

Neutral

Buy

Bionomics Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bionomics Ltd
Bionomics Ltd
-0.67%
-49.15%
-67.49%
-95.96%
-95.96%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bionomics Ltd
Bionomics Ltd
NA
NA
NA
0.0
-0.81
-0.35
NA
2.72
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bionomics Ltd
Bionomics Ltd
Buy
$7.9M
-95.96%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Bionomics Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 344.22K → 98.93K (in $), with an average decrease of 71.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -4.93M → -10.47M (in $), with an average decrease of 55.7% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 104.6%

Institutional Holdings

  • Armistice Capital, LLC

    9.26%

  • Point72 Asset Management, L.P.

    2.39%

  • TWO SIGMA SECURITIES, LLC

    0.20%

  • Lewis Asset Management LLC

    0.17%

  • Two Sigma Investments LLC

    0.12%

  • Beacon Pointe Advisors, LLC

    0.08%

Company Information

bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and alzheimer's disease. our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. we are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. this portfolio is fed by highly productive drug discovery platforms which includes multicore®, our proprietary chemistry capability. at the core of our business is strategic partnering. we partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. this means we can focus our strengths in innovative drug discovery to extract as many "shots on goal"​ from our diverse pipeline in the quest to create the world's new blockbuster drugs. we have a passion for

Organization
Bionomics Ltd
Employees
0
CEO
Dr. Spyridon Papapetropoulos M.D., Ph.D.
Industry
Miscellaneous

Discover More

FAQs